BURLINGTON, N.C. - Labcorp (NYSE: LH) has announced the FDA approval of its nAbCyte Anti-AAVRh74var HB-FE Assay, a diagnostic tool designed to test patient eligibility for Pfizer’s hemophilia B gene therapy, BEQVEZ. This companion diagnostic assay is the first of its kind to receive FDA approval, marking a significant milestone in the treatment of genetic disorders.
The nAbCyte cell-based neutralizing antibody assay is integral to Pfizer (NYSE:PFE)'s gene therapy program, which aims to deliver recombinant adeno-associated virus (rAAV)-based treatments to the right patients. For those considering BEQVEZ, a one-time hemophilia B therapy, testing for preexisting anti-AAVRh74var antibodies is crucial. The presence of these antibodies could potentially affect the safety and efficacy of the treatment.
Dr. Brian Caveney, President of Early Development Research Laboratories at Labcorp and Chief Medical and Scientific Officer, emphasized the company's commitment to advancing cell and gene therapy. He stated that the nAbCyte assay represents a pioneering breakthrough that will help transform therapeutic approaches and patient care for rare genetic conditions.
Hemophilia B is a rare inherited disorder affecting approximately 6,000 people in the United States, leading to prolonged bleeding due to Factor IX deficiency. With up to 60% of the U.S. population estimated to have preexisting anti-AAV antibodies, the need for the nAbCyte CDx test is evident to ensure patient suitability for BEQVEZ therapy.
Dr. Sonal Bhatia of Pfizer’s U.S. Specialty Care Medical Affairs highlighted the importance of the diagnostic in evaluating patient eligibility, as gene therapy treatment paradigms evolve with the introduction of therapies like BEQVEZ.
The nAbCyte test results will be reported as either negative, indicating a patient can be considered for BEQVEZ therapy, or positive. The approval of this diagnostic test expands Labcorp's offerings in cell and gene therapy solutions, which include pre-clinical toxicology, biomarker and companion diagnostic development, and post-commercialization services.
Labcorp, a global provider of laboratory services, plays a pivotal role in diagnostics and drug development, supporting a significant portion of FDA-approved drugs and conducting extensive testing for patients worldwide. This news is based on a press release statement.
InvestingPro Insights
As Labcorp (NYSE: LH) garners attention with the FDA approval of its groundbreaking nAbCyte Anti-AAVRh74var HB-FE Assay, investors and industry observers are closely monitoring the company's financial health and market position. Labcorp's market capitalization stands at a robust $16.73 billion, reflecting investor confidence in its extensive portfolio of diagnostics and drug development services.
Understanding the company's valuation metrics, Labcorp's Price/Earnings (P/E) ratio currently sits at 39.44, which adjusts to a more favorable 23.89 when looking at the last twelve months as of Q1 2024. This suggests that investors may be expecting higher earnings growth in the future compared to the current earnings level. Additionally, the company's Price to Book (P/B) ratio as of Q1 2024 is 2.1, indicating that the stock is trading at a little over twice its book value.
Despite the recent FDA approval potentially bolstering future revenue streams, Labcorp has experienced a revenue decline of -16.72% over the last twelve months as of Q1 2024. However, a quarterly revenue growth of 4.57% in Q1 2024 indicates a potential turnaround or seasonal fluctuation in sales. Investors should also note Labcorp's dividend yield of 1.45%, which adds an element of income to the investment.
An InvestingPro Tip to consider is the company's fair value estimation. According to InvestingPro, Labcorp's fair value stands at $186.68, which is below the analyst target of $241 but above the previous close price of $198.35. This discrepancy suggests there may be room for price appreciation, and investors can explore this further with the additional 15 InvestingPro Tips available on the platform. For those interested in deepening their analysis, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
With the recent FDA approval potentially setting the stage for revenue growth and the company's commitment to innovation in diagnostics and drug development, Labcorp's financials and market performance will remain key areas of interest for stakeholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.